Propanc Biopharma (NASDAQ:PPCB – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Valuation & Earnings
This table compares Propanc Biopharma and Absci”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Propanc Biopharma | N/A | N/A | -$58.92 million | ($24.25) | -0.05 |
| Absci | $2.80 million | 467.70 | -$115.18 million | ($0.83) | -10.12 |
Analyst Recommendations
This is a summary of current recommendations for Propanc Biopharma and Absci, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Propanc Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Absci | 1 | 0 | 8 | 0 | 2.78 |
Absci has a consensus price target of $13.43, indicating a potential upside of 59.86%. Given Absci’s stronger consensus rating and higher possible upside, analysts clearly believe Absci is more favorable than Propanc Biopharma.
Profitability
This table compares Propanc Biopharma and Absci’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Propanc Biopharma | N/A | -151.28% | -109.53% |
| Absci | -6,450.76% | -66.32% | -57.01% |
Volatility and Risk
Propanc Biopharma has a beta of 3.52, indicating that its stock price is 252% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.
Institutional & Insider Ownership
52.0% of Absci shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Absci beats Propanc Biopharma on 8 of the 13 factors compared between the two stocks.
About Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
